LM

LM Funding America Achieves Over 648% Revenue Growth to $13.0 Million for 2023

Retrieved on: 
Monday, April 1, 2024
LM, Telephone, Mining, Investment, BTC, Total, Cryptocurrency

Richard Russell, Chief Financial Officer of LM Funding, further noted, "We ended the year with cash plus Bitcoin, valued as of December 31, 2023, of approximately $5.8 million.

Key Points: 
  • Richard Russell, Chief Financial Officer of LM Funding, further noted, "We ended the year with cash plus Bitcoin, valued as of December 31, 2023, of approximately $5.8 million.
  • Our working capital stood at $7.4 million as of December 31, 2023, and the equity of LM Funding shareholders was $36.2 million, or $14.52 per share.
  • Total revenue for the year ended December 31, 2023, was approximately $13.0 million, an increase of $11.3 million, or more than 648%, from $1.7 million in 2022.
  • Core EBITDA loss for the twelve months ended December 31, 2023, totaled approximately $0.2 million, compared with Core EBITDA loss of $6.5 million in 2022.

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Retrieved on: 
Monday, March 25, 2024
Diagnosis, Certification, LM, Plus Therapeutics, NSCLC, CSF, Partnership, Central nervous system, Patient, CNS, Breast, PSTV, Lung cancer, Clinical trial, Therapy, Cancer, Rhenium, CLIA, Research institute, Cancer prevention, Feinberg School of Medicine, Associate professor

AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has successfully completed key validation testing and implementation of its tumor cell enumeration assay, known as CSF-01, to be used initially as an exploratory endpoint in its ReSPECT-LM clinical trials.

Key Points: 
  • “In mid-2023, the Company licensed CSF-01, as well as a broader CSF diagnostic testing portfolio due to high conviction that routine implementation will substantially improve diagnosis and clinical management of LM,” said Marc H. Hedrick, M.D., President & CEO of Plus Therapeutics.
  • While validated for use in Plus’ clinical development programs, full Clinical Laboratory Improvement Amendments (CLIA) certification is not anticipated until 2025.
  • The ReSPECT-LM trial, including support for CSF-01 testing, is currently receiving grant funding from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • If the FORSEE data is positive, we intend to work toward increasing commercial reimbursement for the CLIA-certified test and explore partnerships to maximize diagnostic utilization for the broader CNS cancer space.

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
NMIBC, Research, BCG, LM, Bacillus, Patient, LMS, Cancer, Investment, Therapy, Injection, POC, Carcinoma, CIS, Food, Pharmaceutical industry

As of December 31, 2023, cash, cash equivalents, and investments in marketable debt securities totaled $65.6 million.

Key Points: 
  • As of December 31, 2023, cash, cash equivalents, and investments in marketable debt securities totaled $65.6 million.
  • The fourth quarter and full year increases were primarily due to an increase in expenses related to clinical trials and non-clinical activities for TARA-002.
  • Net loss for the fourth quarter of 2023 included approximately $1.5 million of stock-based compensation expenses.
  • Net loss for the year ended December 31, 2023 included approximately $6.1 million of stock-based compensation expenses.

1stWest M&A Names Derek Koecher as a New Senior Advisor

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Other Construction & Property, Finance, Construction & Property, Consulting, Banking, Lumen Technologies, Risk, Derek, Mergers and acquisitions, Senior, VZ, LM, Senior advisor, Software as a service, Sale

1stWest Mergers and Acquisitions announced today that it has named Derek Koecher as a new Senior Advisor.

Key Points: 
  • 1stWest Mergers and Acquisitions announced today that it has named Derek Koecher as a new Senior Advisor.
  • Derek will bring his decades of M&A expertise to help guide 1stWest M&A’s clients through complex carve-outs, buy and sell transactions, growth strategies, and negotiation of transaction compensation for founders and executive teams.
  • “Derek is among the most sought-after advisors for transactions in the hottest M&A sectors today, from telecom and SaaS to AI,” said Ted Rieple, 1stWest M&A’s Managing Partner.
  • We are thrilled to welcome him as a Senior Advisor.”

Guide Sensmart Built R&D and Production System of Full Infrared Industry Chain

Retrieved on: 
Wednesday, April 3, 2024
Momentum, LM, Algorithm, Infrared, Night vision, Artificial intelligence, Software, People's Daily, Telescope

Over the years, Guide sensmart ("the Company") has been dedicated to technology innovation.

Key Points: 
  • Over the years, Guide sensmart ("the Company") has been dedicated to technology innovation.
  • "In the past, the personnel should check hundreds of points in thermal power station, it often took several days."
  • R&D manager Cui of Guide sensmart introduced, "now inspection personnel can monitor the status of all equipment in real time, sitting in the control center."
  • Guide sensmart will continue to insist on technology innovation, applying infrared technology to meet customer needs to provide more professional, efficient and convenient solutions.

Exostar Enhances The Exostar Platform's Onboarding Module to Include Defense Industrial Base's Cybersecurity Compliance and Risk Assessment

Retrieved on: 
Tuesday, March 19, 2024
Department of Defence, LM, Supply chain, CCRA, Innovation, Risk management, Cybersecurity Maturity Model Certification, Working Group, Risk, Huntington Ingalls Industries, National security, Rolls-Royce, Risk assessment, CMMC, OBM, Senior, Supply, CSQ, NIST, Certification, Lockheed Martin, Computer security, Completeness, Grumman, Microsoft Excel, RTX, Defense industrial base, BAE Systems, DIB

HERNDON, Va., March 19, 2024 /PRNewswire/ -- Exostar, a leader in trusted, secure business collaboration and NIST 800-171 and CMMC solutions for the aerospace and defense industry, today announced The Exostar Platform's Onboarding Module now supports the Cybersecurity Compliance and Risk Assessment (CCRA).  Prime contractors throughout the Defense Industrial Base (DIB) have begun to use the CCRA to gather cybersecurity information from the companies throughout their global, multi-tiered supply chains to assess compliance, understand and manage risk, and evaluate partnerships.

Key Points: 
  • Exostar's Onboarding Module automates the delivery, completion & sharing of the CCRA across the Exostar community.
  • The CCRA provides a standardized, consistent means for collecting cybersecurity compliance data and calculating supplier risk.
  • The Exostar Platform's Onboarding Module , which provides supplier visibility and risk management functionality throughout the relationship life cycle, automates the completion and sharing of the CCRA, adding even greater value.
  • "Now, all DIB companies can leverage The Exostar Platform's Onboarding Module to accelerate CCRA adoption."

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Retrieved on: 
Monday, March 11, 2024
Fast Track, Breast cancer, Central nervous system, PSTV, Cohort, Rhenium, FDA, Cancer, Data monitoring committee, Learning, Therapy, CNS, Plus Therapeutics, Patient, DSMB, LM, Pharmaceutical industry

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.

Key Points: 
  • Three patients were dosed as part of Cohort 5, bringing the total to 18 patients dosed in the ReSPECT-LM trial to date.
  • There have been no dose limiting toxicities observed to date with administered radiation doses up to 66.14 millicuries in Cohort 5, a ten-fold increase over Cohort 1.
  • The Company plans to initiate dosing in Cohort 6 in the second quarter of 2024, pending Data Safety Monitoring Board (DSMB) approval.
  • In addition, five new clinical trial sites were added to this trial over the last year, bringing the total number of sites to seven.

LM Funding Announces 1-for-6 Reverse Stock Split to Ensure Compliance with Nasdaq Continued Listing Requirements and to Attract a Broader Audience of Investors

Retrieved on: 
Friday, March 8, 2024
Certificate, CUSIP, LM, Security (finance)

Beginning March 12, 2024, LM Funding’s common stock will trade on a split-adjusted basis.

Key Points: 
  • Beginning March 12, 2024, LM Funding’s common stock will trade on a split-adjusted basis.
  • LM Funding’s shares of common stock will continue to trade on the NASDAQ under the symbol “LMFA.” The new CUSIP number for the Company’s common stock post reverse stock split is 502074503.
  • Upon the effectiveness of the reverse stock split, every 6 shares of LM Funding’s issued and outstanding common stock will automatically be converted into one share of common stock.
  • Any fraction of a share of common stock that would be created as a result of the reverse stock split be rounded up to the next whole share.

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 5, 2024
Glioblastoma, Breast cancer, PSTV, Rhenium, Decompression (diving), FDA, Food, GMP, PD-1, Ependymoma, Conference, Safety, Plus Therapeutics, Respect, Therapy, Food and Drug Administration, Webcast, Patient, CSF, LM, PD-L1, Pharmaceutical industry

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.
  • Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated dose, and recommended Phase 2 dose.
  • Implement Plus’ CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay as an exploratory clinical endpoint in all ReSPECT-LM trial patients in Q1 2024.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

Four Frederick Business Leaders Graduate from Leadership Maryland

Retrieved on: 
Tuesday, February 13, 2024
Human services, Economic development, Education, City, Calibration, Housing, Growth, Federation, Government, Health, Organization, Orientation, Assistant director, Laboratory, LM, Environment, Management

FREDERICK, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Four local Frederick County leaders recently graduated from Leadership Maryland '23. The group completed the professional development program dedicated to building a better Maryland by harnessing the strength of its local business and community leaders. Frederick County program graduates include: Jodie Bollinger, Director of Frederick County Office of Economic Development, Randy Querry, Director of Government Relations, A2LA, Mary Ford-Naill, Manager of Economic Development, and Dr. Ashley Waters, Assistant Director, Department of Housing and Human Services, both with The City of Frederick. Leadership Maryland honored the local leaders, and the entire Class of 2023 at its 30th graduation ceremony held December 5 at the Hilton Baltimore BWI Airport. As program graduates, these Frederick area leaders are now members of Leadership Maryland's powerful alumni network, consisting of more than 1,300 esteemed leaders from all industries and regions of the state.

Key Points: 
  • FREDERICK, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Four local Frederick County leaders recently graduated from Leadership Maryland '23.
  • Leadership Maryland honored the local leaders, and the entire Class of 2023 at its 30th graduation ceremony held December 5 at the Hilton Baltimore BWI Airport.
  • As program graduates, these Frederick area leaders are now members of Leadership Maryland's powerful alumni network, consisting of more than 1,300 esteemed leaders from all industries and regions of the state.
  • These Frederick leaders were amongst 48 individuals chosen by a committee to complete Leadership Maryland's eight-month hands-on learning program.